These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 30961500)

  • 1. Pharmacological Management of Diabetic Nephropathy.
    Papademetriou V; Alataki S; Stavropoulos K; Papadopoulos C; Bakogiannis K; Tsioufis K
    Curr Vasc Pharmacol; 2020; 18(2):139-147. PubMed ID: 30961500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
    Zou H; Zhou B; Xu G
    Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming the Care of Patients with Diabetic Kidney Disease.
    Brosius FC; Cherney D; Gee PO; Harris RC; Kliger AS; Tuttle KR; Quaggin SE;
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1590-1600. PubMed ID: 34103350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.
    Ninčević V; Omanović Kolarić T; Roguljić H; Kizivat T; Smolić M; Bilić Ćurčić I
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31757028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential for improved outcomes in the prevention and therapy of diabetic kidney disease through 'stacking' of drugs from different classes.
    Bell DSH; Jerkins T
    Diabetes Obes Metab; 2024 Jun; 26(6):2046-2053. PubMed ID: 38516874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
    Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
    Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists.
    Prattichizzo F; de Candia P; Ceriello A
    Metabolism; 2021 Jul; 120():154799. PubMed ID: 34029597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of renin-angiotensin system blockers on renal and cardiovascular outcomes in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.
    Liu X; Ma L; Li Z
    J Endocrinol Invest; 2020 Jul; 43(7):959-972. PubMed ID: 31939197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with SGLT2 inhibitors for diabetic kidney disease.
    Cai Y; Liu X; Xu G
    Biomed Pharmacother; 2020 Jul; 127():110192. PubMed ID: 32559844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.
    Li J; Albajrami O; Zhuo M; Hawley CE; Paik JM
    Clin J Am Soc Nephrol; 2020 Nov; 15(11):1678-1688. PubMed ID: 32518100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetic nephropathy and multiorgan protection. Part II.
    Gluhovschi G; Gluhovschi C; Vlad A; Timar R; Bob F; Velciov S; Bozdog G; Petrica L
    Rom J Intern Med; 2011; 49(4):237-49. PubMed ID: 22568268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin Angiotensin Aldosterone System (RAAS): its biology and drug targets for treating diabetic nephropathy.
    Zain M; Awan FR
    Pak J Pharm Sci; 2014 Sep; 27(5):1379-91. PubMed ID: 25176370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
    Sloan LA
    J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes.
    Marathias KP; Lambadiari VA; Markakis KP; Vlahakos VD; Bacharaki D; Raptis AE; Dimitriadis GD; Vlahakos DV
    Am J Nephrol; 2020; 51(5):349-356. PubMed ID: 32241009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [GLP-1 receptor agonists : impact on diabetic kidney disease].
    Wéra M; Paquot N
    Rev Med Suisse; 2024 Aug; 20(884):1488-1491. PubMed ID: 39219391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic Kidney Disease.
    Tong L; Adler SG
    Clin J Am Soc Nephrol; 2018 Feb; 13(2):335-338. PubMed ID: 29046291
    [No Abstract]   [Full Text] [Related]  

  • 18. Two cases of advanced stage rapidly progressive diabetic nephropathy effectively treated with combination therapy including RAS blocker, GLP-1 receptor agonist and SGLT-2 inhibitor.
    Morino J; Hirai K; Kaneko S; Minato S; Yanai K; Mutsuyoshi Y; Ishii H; Matsuyama M; Kitano T; Shindo M; Aomatsu A; Miyazawa H; Ito K; Ueda Y; Hoshino T; Ookawara S; Hara K; Morishita Y
    CEN Case Rep; 2019 May; 8(2):128-133. PubMed ID: 30663011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
    St Peter WL; Odum LE; Whaley-Connell AT
    Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual Renin-Angiotensin-Aldosterone System Inhibition for the Treatment of Diabetic Kidney Disease: Adverse Effects and Unfulfilled Promise.
    El-Haddad B; Reule S; Drawz PE
    Curr Diab Rep; 2015 Oct; 15(10):70. PubMed ID: 26275442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.